Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug market with Pomalyst (pomalidomide) long after it should have faced competition from generic alternative
Bristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst.
Bristol Myers Squibb has been
accused in a new lawsuit of using fraudulent patents and other
illegal tactics to maintain its monopoly on blockbuster blood
cancer drug Pomalyst for years after it.
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit By Reuters investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.
Bristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years after it should have faced generic competition. In a complaint filed on Tuesday in Manhattan federal court, Blue Cross Blue Shield of Louisiana said the company violated U.S. antitrust law and had caused purchasers of the drug to overpay "by many hundreds of millions, if not billions, of dollars." The health insu